CHARM Therapeutics is a 3D deep learning research company discovering and developing transformational medicines. The facility will act as the new research & development (R&D) site for CHARM Therapeutics, providing the Company with the necessary capacity to support its growth plans as it continues to develop its transformational oncology pipeline.  Babraham Research Campus is an internationally recognized life sciences cluster, with over 60 companies and 2,000 employees co-located with the Babraham Institute providing shared facilities and supporting programs. The Campus is one of…

The Skeletal Muscle Differentiation kit from AMSBIO provides a unique protocol to differentiate human pluripotent stem cells to skeletal muscle with high yields and without cell sorting or genetic manipulation. Now available with the option of simple to use control myoblasts, stem cell researchers looking to differentiate stem cells to skeletal muscle with multinucleated myotubes can produce consistent, high-quality results every time. Methods for studying muscular disease and potential therapies were, until recently, dependent on invasive muscle biopsies to produce limited batches of…

 April’s eNews is here to continue the #lifesciences conversation on:✅ Upcoming Events✅ Storytelling in Corporate Communication✅ Our Collaboration with United Airlines✅ Meet our Ecosystem in our Annual Review✅ ON Helix✅ Cambridge Facilities and Lab SpaceRead it here

Arecor Therapeutics plc (“Arecor” or the “Group”) ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER - Manjit is an accomplished strategic deal-maker bringing 25+ years of scientific, commercial and financial experience across major global pharmaceutical and biotechnology companies, specialising in product in and out-licensing, commercial strategy, accelerating growth and M&A - Will play a key role in building and executing Arecor’s ambitious commercialisation and growth plans as pipeline of proprietary and partnered products advances Cambridge, UK, 5 April 2023: Arecor…

Arecor Therapeutics plc (“Arecor” or the “Group”) FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED, ULTRA-RAPID ACTING INSULIN CANDIDATE - Disrupter insulin with potential to be the first ultra-concentrated and ultra-rapid acting insulin available for patients - AT278 aims to significantly improve post prandial glucose control and reduce injection volume and potentially enable fewer injections per day for people with Type 2 diabetes who have high insulin needs - Ultra-concentrated, ultra-rapid acting insulin such as AT278 is critical to development of next…

Contract Research Organizations (CROs) have become vital partners in the drug development process, enabling biotech and pharmaceutical companies to develop and market life-saving drugs. To further understand the supply chain complexities for CROs, Biocair recently conducted a qualitative research study with CRO supply chain professionals. The study involved 45-minute business interviews with supply chain professionals working for CROs. The results of the study have proved instrumental for Biocair in furthering its understanding of the intricacies facing CROs and how logistics play a vital…

Economic data shows uplifting effect on employment across both Knowledge Intensive (KI) and non-KI sectors in the Cambridgeshire and Peterborough region. Cambridge, UK. 4th April 2023: The latest in-depth analysis on the Cambridge city region economy from Cambridge Ahead, produced by the Centre for Business Research (CBR) at the University of Cambridge, shines a spotlight on science and innovation-led job creation that is fuelling a buoyant and resilient corporate economy, and is increasingly having a positive effect on job creation across wider (non-KI) sectors in the wider Cambridgeshire…

NRG Therapeutics Announces International Scientific Advisory Board Stevenage, UK, 30 March 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board (SAB), to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders. The four founding members of NRG’s International SAB are US-based and bring in-depth translational expertise in neuroscience and drug discovery across chemistry, biology and pharmacology…

In a fiercely competitive recruitment market, how do you make your company irresistible to the best tech talent? St John's Innovation Centre, in collaboration with Innovate UK EDGE, Taylor Vinters and tech executive search firm Bailey Fisher, are planning an event that will offer invaluable insight into the ways in which founders of tech businesses can recruit and retain talent effectively. The session will share advice on employee engagement, employment structures, corporate culture/purpose, hybrid working/4 day week, DEI, vacancy marketing and hiring practices while also exploring the…

Pharmaron announced today that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSMIF) to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM. This major expansion project will provide a four-fold increase in gene therapy process development and analytical capacity accommodating viral vector, DNA and RNA drug substance, plus drug product formulation. The expansion includes 3,500 sqM for future commercial scale GMP capacity. The resulting facility will greatly…